Pulmatrix touts Ph1 data for inhaled COPD therapy

Pulmatrix (NSDQ:PULM) touted data today from a dose-ranging Phase I trial of its once-daily inhaled therapy designed for people with chronic obstructive pulmonary disease. The company’s product is a reformulation of tiotropium bromide, the active component in Boehringer Ingelheim’s blockbuster drug, Spiriva. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix touts Ph1 data for inhaled COPD therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Related Links:

Authors: Zhang Y, Hu C, Bian Z, Chen P Abstract There are a lot of controversies pertaining to correctness of timing for the initiation of dialysis in chronic kidney disease (CKD) patients. The present study was conducted to examine the potential association of initiation timing of dialyses with long-term prognosis in CKD patients. In total, 294 patients confirmed as end-stage renal disease (ESRD) were included as study subjects. According to the estimated glomerular filtration rate (eGFR) at initiation time, the patients were classified into four groups based on eGFR: ≥10.5, 8-10.4, 6-8 and
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Abstract Chronic obstructive pulmonary disease (COPD) is a disorder affecting more than 200 million people around the world, resulting in three million deaths per year. COPD is characterized by the loss of lung tissue and airway remodelling, with chronic inflammation of the airways and progressive destruction of lung parenchyma. The use of stem cells may lead to regenerative processes that address biological damage. However, this approach raises ethical issues that need to be considered in clinical trials using stem cell therapy, such as informed consent, patient recruitment and harm minimization, as well as the i...
Source: Clin Med Res - Category: Research Authors: Tags: J Clin Med Res Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS Inhibited CXCL10 protects against COPD progression by decreasing secretion of inflammatory factors, which provides a new direction for the clinical prevention and treatment of COPD. PMID: 30118441 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Conclusion: Decreased subfoveal choroid thickness was found in the COPD patients both during an exacerbation and in the stable period, when compared to the control group. The mean RNFL thickness was similar in the exacerbation and stable period of the stable COPD patients when compared to the control group. This suggests that ocular findings might be important in terms of COPD morbidity. This trial is registered with www.chictr.org.cn/enIndex.aspx. PMID: 30116623 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
In conclusion, the present study demonstrated that the common DEGs may be associated with the progression of severe pneumonia. PMID: 30112034 [PubMed]
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M1R, M3R and M5R selectively couple to Gq/G11; M2R and M4R selectively couple to Gi/Go. M3 muscarinic ACh receptors are present in the central nervous system and the periphery.M3R knockout mice are viable and fertile, and have no major morphological abnormalities. They have a lean phenotype. This results from a combination of reduced caloric intake and increased energy expenditure. They eat less food than wild-type mice, possibly because a central cholinergic pathway that stimulates food intake is disrupted. They also expend more e...
Source: NIDDK Research Resources - Category: Endocrinology Source Type: research
Condition:   COPD Intervention:   Other: Dance Sponsors:   West Park Healthcare Centre;   Canadian Lung Association Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Alpha 1-Antitrypsin Deficiency;   Emphysema;   COPD Interventions:   Drug: Placebo Oral Tablet;   Drug: Alvelestat oral tablet - dose 1;   Drug: Alvelestat oral tablet - dose 2 Sponsors:   Mereo BioPharma;   Syneos Health Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD Intervention:   Other: Dance Sponsors:   West Park Healthcare Centre;   Canadian Lung Association Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Obstructive Pulmonary | Clinical Trials | Medical Devices | Respiratory Medicine | Spiriva | Tiotropium